Drug manufacturer Lilly indicated late last week that it reserves the right to seek additional compensation for its products from 340B covered entities if it learns later that it charged them less than what the company perceives the 340B statute
…
Category: Regulatory
President Joe Biden today during a major speech on drug pricing reform applauded U.S. Rep. Abigail Spanberger (D-Va.) for being “relentless in making sure” that the 340B statute “is actually enforced.”
Biden and U.S. Health and Human Services (HHS) Secretary
…
President Joe Biden and U.S. Health and Human Services (HHS) Secretary Xavier Becerra are scheduled to speak on Monday, Feb. 14, during the National Association of Community Health Centers’ Policy and Issues Virtual Forum, NACHC announced on Tuesday.
Securing Biden
…
The U.S. Health Resources and Services Administration (HRSA) said yesterday it knows of three hospitals that have withdrawn from the 340B program because changes in patient mix linked to the COVID-19 pandemic caused them to lose their eligibility. There could
…
340B program federal administrators told health care providers attending the 340B Coalition winter conference in San Diego today that they are behind them in the battle with drug manufacturers over accessing 340B pricing in the contract pharmacy setting.
The U.S.
…
The U.S. Health Resources and Services Administration (HRSA) told drug manufacturer Celgene nearly five years ago the company “must ensure” that covered entities could buy its cancer drugs Revlimid, Pomalyst, and Thalomid at the 340B ceiling price through Celgene’s limited
…
A Vermont community health center that co-initiated 340B administrative dispute resolution (ADR) proceedings against AstraZeneca over its conditions on 340B contract pharmacy yesterday asked the panel hearing its claim to deny the drug company’s motion to stay the proceedings.
Little
…
Three drug manufacturers—including two that have imposed conditions on 340B contract pharmacy—posted public notices this week to 340B covered entities about refunds for charges above 340B ceiling prices.
Bristol Myers Squibb (BMS) and Novo Nordisk’s notices came to light yesterday
…
340B program flexibilities will continue under the eighth 90-day extension of the COVID-19 national public health emergency (PHE) late last week.
U.S. Health and Human Services (HHS) Secretary Xavier Becerra renewed the PHE on Friday, Jan. 14.
…
The Centers for Medicare & Medicaid Services (CMS) yesterday proposed changing Medicare Part D rules to curb plan sponsors and pharmacy benefit managers’ skyrocketing use of direct and indirect renumeration fees (DIR)—PBMs’ controversial practice of clawing back drug payments to
…